E77.0
BillableDefects in post-translational modification of lysosomal enzymes
HCC Category Mapping
What This Code Means
A rare genetic disorder affecting how the body modifies and processes lysosomal enzymes, which are proteins that break down waste materials in cells.
Coding Tips
- •This code requires documentation of the specific enzyme defect when available
- •Often associated with lysosomal storage diseases; review clinical findings for more specific diagnosis
Clinical Significance
Defects in post-translational modification of lysosomal enzymes includes mucolipidosis II (I-cell disease) and mucolipidosis III (pseudo-Hurler polydystrophy), where lysosomal enzymes are not properly tagged for delivery to lysosomes. These are severe conditions with clinical features overlapping MPS but with distinct pathophysiology, requiring differentiation for appropriate genetic counseling and management.
Documentation Requirements
- ✓Specific disorder documented: mucolipidosis II (I-cell disease) or mucolipidosis III (pseudo-Hurler polydystrophy)
- ✓Confirmatory testing: elevated serum lysosomal enzyme levels, decreased intracellular enzyme activity, or GNPTAB/GNPTG gene mutations
- ✓Clinical manifestations: skeletal abnormalities, coarse features, developmental delay, cardiac involvement
- ✓Differentiation from MPS documented (different enzyme trafficking defect mechanism)
- ✓Treatment plan and current disease status